Product nameAnti-SIRT4 antibody
See all SIRT4 primary antibodies
DescriptionRabbit polyclonal to SIRT4
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Mouse, Rat, Human
Synthetic peptide surrounding amino acid 72 of Rat SIRT4.
- Rat kidney tissue lysate
General notesThe antibody solution should be gently mixed before use
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Storage bufferpH: 7.20
Preservative: 0.01% Thimerosal (merthiolate)
Constituents: 69% PBS, 0.15% EDTA, 30% Glycerol, 0.5% BSA
Concentration information loading...
PurityProtein A purified
- Epigenetics and Nuclear Signaling
- Chromatin Modifying Enzymes
- Class III / Sir2 class
- Pathways and Processes
- Metabolic signaling pathways
- Energy transfer pathways
- Energy Metabolism
Our Abpromise guarantee covers the use of ab124521 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use a concentration of 1 - 4 µg/ml. Predicted molecular weight: 32 kDa.|
FunctionActs as NAD-dependent protein lipoamidase, ADP-ribosyl transferase and deacetylase. Catalyzes more efficiently removal of lipoyl- and biotinyl- than acetyl-lysine modifications. Inhibits the pyruvate dehydrogenase complex (PDH) activity via the enzymatic hydrolysis of the lipoamide cofactor from the E2 component, DLAT, in a phosphorylation-independent manner (PubMed:25525879). Catalyzes the transfer of ADP-ribosyl groups onto target proteins, including mitochondrial GLUD1, inhibiting GLUD1 enzyme activity. Acts as a negative regulator of mitochondrial glutamine metabolism by mediating mono ADP-ribosylation of GLUD1: expressed in response to DNA damage and negatively regulates anaplerosis by inhibiting GLUD1, leading to block metabolism of glutamine into tricarboxylic acid cycle and promoting cell cycle arrest (PubMed:16959573, PubMed:17715127). In response to mTORC1 signal, SIRT4 expression is repressed, promoting anaplerosis and cell proliferation. Acts as a tumor suppressor (PubMed:23562301, PubMed:23663782). Also acts as a NAD-dependent protein deacetylase: mediates deacetylation of 'Lys-471' of MLYCD, inhibiting its activity, thereby acting as a regulator of lipid homeostasis (By similarity). Controls fatty acid oxidation by inhibiting PPARA transcriptional activation. Impairs SIRT1:PPARA interaction probably through the regulation of NAD(+) levels (PubMed:24043310). Down-regulates insulin secretion.
Tissue specificityDetected in vascular smooth muscle and striated muscle. Detected in insulin-producing beta-cells in pancreas islets of Langerhans (at protein level). Widely expressed. Weakly expressed in leukocytes and fetal thymus.
Sequence similaritiesBelongs to the sirtuin family. Class II subfamily.
Contains 1 deacetylase sirtuin-type domain.
Cellular localizationMitochondrion matrix.
- Information by UniProt
- MGC130046 antibody
- MGC130047 antibody
- MGC57437 antibody
This product has been referenced in:
- Fukushima A et al. Acetylation contributes to hypertrophy-caused maturational delay of cardiac energy metabolism. JCI Insight 3:N/A (2018). Read more (PubMed: 29769443) »
- Hu JQ et al. Histone deacetylase SIRT6 regulates chemosensitivity in liver cancer cells via modulation of FOXO3 activity. Oncol Rep 40:3635-3644 (2018). Read more (PubMed: 30542728) »